Analyst Ratings for Sangamo Therapeutics
Portfolio Pulse from Benzinga Insights
Sangamo Therapeutics (NASDAQ:SGMO) has received 6 bullish ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for the stock, according to 6 analysts, is $6.83, a decrease of 28.85% from the previous average of $9.60.
August 15, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sangamo Therapeutics has received positive analyst ratings, but the decrease in the average price target could impact the stock negatively.
While the company has received positive ratings from analysts, the decrease in the average price target suggests a potential decrease in the stock price. This could lead to a negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100